Systemic AAV9-IFNβ gene delivery treats highly invasive glioblastoma

Neuro-Oncology

Volumn 18, Issue 11, 2016, Pages 1508-1518

  Guhasarkar, Dwijit ^a   Su, Qin ^a   Gao, Guangping ^a   Sena Esteves, Miguel ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Adeno associated virus (AAV); glioblastoma (GBM); interferon beta (IFNb); mouse orthotopic xenograft; systemic AAV gene therapy

Indexed keywords

BETA INTERFERON; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BIOLUMINESCENCE; CANCER GROWTH; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; ENDOTHELIUM CELL; GENE DOSAGE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACRANIAL DRUG ADMINISTRATION; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN; ANIMAL; BRAIN; BRAIN NEOPLASMS; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DEPENDOVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; INTERFERON-BETA; MICE; MICE, NUDE;

EID: 84994559228     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now097     Document Type: Article

References (36)

1. Preusser M, de Ribaupierre S,Wohrer A, et al. Current concepts and management of glioblastoma. Ann Neurol. 2011;70(1):9-21.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concom itant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
4. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513-545.
5. Kaynor C, Xin M, Wakefield J, Barsoum J, Qin XQ. D irect evidence that IFN-beta functions as a tumor-suppressor protein. J Interferon Cytokine Res. 2002;22(11):1089-1098.
6. Juang SH, Wei SJ, Hung YM, et al. IFN-beta induces caspase-mediated apoptosis by disrupting mitochondria in human advanced stage colon cancer cell lines. J Interferon Cytokine Res. 2004;24(4):231-243.
7. Streck CJ, Ng CY, Zhang Y, Zhou J, Nathwani AC, Da vidoff AM. Interferon-mediated anti-angiogenic therapy for neuroblastoma. Cancer Lett. 2005;228(1-2):163-170.
8. Xiao HB, Zhou WY, Chen XF, et al. Interferon-beta efficiently inhi bited endothelial progenitor cell-induced tumor angiogenesis. Gene Ther. 2012;19(10):1030-1034.
9. Wolpert F, Happold C, Reifenberger G, et al. Interferon-beta modulates the innate immune re sponse against glioblastoma initiating cells. PLoS One. 2015;10(10):e0139603.
10. Yang X, Zhang X, Fu ML, et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell. 2014;25(1):37-48.
11. Kase S, Kubota T, Watanabe M, et al. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Anticancer Res. 1993;13(2):369-373.
12. Motomura K, Natsume A, Kishida Y, et al. Benefits of interferon-beta and temozolomide combination therapy for newly diag nosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer. 2011;117(8): 1721-1730.
13. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharma cokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res. 2000;20(10): 857-866.
14. Maguire CA, Meijer DH, LeRoy SG, et al. Preventing growth of brain tumors by creating a zone of resistance. Mol Ther. 2008;16(10): 1695-1702.
15. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastomaderived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69( 8):3472-3481.
16. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27(1):59-65.
17. Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther. 2009;17(7):1187-1196.
18. Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther. 2011;19(11): 1971-1980.
19. Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: National Academies Press 2011.
20. Xie J, Xie Q, Zhang H, et al. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol Ther. 2011;19(3):526-535.
21. Yan Z, Yan H, Ou H. Human thyroxine binding globulin (TBG) promoter directs efficient and sustaining transgene expression in liver-specific pattern. Gene. 2012;506(2):289-294.
22. Ayuso E, Mingozzi F , Montane J, et al. High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency. Gene Ther. 2010;17(4):503-510.
23. Chen BD, He CH, Chen XC, et al. Targeting transgene to the heart and liver with AAV9 by different promoters. Clin Exp Pharmacol Physiol. 2015;42(10):1108-1117.
24. Ligon KL, Alberta JA, Kho AT, et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. 2004;63(5):499-509.
25. Trepant AL, Bouchart C, Rorive S, et al. Identification o f OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms. Tumour Biol. 2015;36(3):1943-1953.
26. Crommentuijn MH, M aguire CA, Niers JM, et al. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. Mol Oncol. 2016;10(4):625-634.
27. Go dlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S. microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle. 2010;9(14):2742-2748.
28. Williams SP, Nowicki MO, Liu F, et al. Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res. 2011; 71(16):5374-5380.
29. Nevo I, Woolard K, Cam M, et al. Identification of molecular pathways facilitating glioma cell invasion in situ. PLoS One. 2014;9(11):e111783.
30. Streck CJ, Dickson PV, Ng CY, et al. Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Ther. 2006;13(1):99-106.
31. Harari D, Abramovich R, Zozulya A, et al. Bri dging the species divide: transgenic mice humanized for type-I interferon response. PLoS One. 2014;9(1):e84259.
32. Qin XQ, Beckham C, Brown JL, Lukashev M, Barsoum J. Human and mouse IF N-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol Ther. 2001;4(4): 356-364.
33. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulatio n, antiviral response and virus countermeasures. J Gen Virol. 2000;81(Pt 10):2341-2364.
34. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67: 227-264.
35. Fujimaki T, Ishii H, Matsuno A, Arai H, Nakagomi T. Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory re current anaplastic astrocytoma. World J Surg Oncol. 2007;5:89.
36. Shen D, Guo CC, Wang J, et al. Interferon-alpha/beta enhances temozolomide activity against MGMT-positive glioma stem-like cells. Oncol Rep. 2015;34(5):2715-2721.